Suppr超能文献

奎宁和奎尼丁在健康泰国男性体内的药代动力学和药效学特性比较。

A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.

作者信息

Karbwang J, Davis T M, Looareesuwan S, Molunto P, Bunnag D, White N J

机构信息

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

出版信息

Br J Clin Pharmacol. 1993 Mar;35(3):265-71.

Abstract
  1. Eight healthy Thai males, aged 19-27 years, received quinine or quinidine dihydrochloride 10 mg kg-1 body weight by intravenous infusion over 1 h. At least 1 week later, the alternative alkaloid was administered. 2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01). Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2). 3. Side-effects, including transient hypotension after quinidine in two cases, were mild. 4. Both drugs produced prolongation of the rate-corrected QT interval (QTc), with similar rates of elimination from the cardiac conduction 'effect' compartment (keo; 4.14 [0.03-15.33] h-1 for quinine, 3.74 [1.63-13.14] h-1 for quinidine, P > 0.19). Using a linear concentration-response model, the intercept ('threshold') for quinidine effect was lower than that for quinine (P = 0.004) but the slopes (change in QTc for a given change in free drug concentration) were similar (P = 0.56).(ABSTRACT TRUNCATED AT 250 WORDS)
摘要
  1. 八名年龄在19至27岁之间的健康泰国男性,通过静脉输注在1小时内接受了每千克体重10毫克的奎宁或二盐酸奎尼丁。至少1周后,给予另一种生物碱。2. 奎尼丁的终末消除半衰期短于奎宁(中位数[范围]:5.7[5.0 - 10.0]小时对9.9[8.8 - 15.1]小时,P < 0.01),奎尼丁的稳态分布容积(Vss)大于奎宁(3.5[2.5 - 5.6]对3.1[1.8 - 4.1]升/千克;P = 0.02),且奎尼丁与血浆蛋白的结合较少(游离药物百分比:22.8[15.4 - 47.2]%对9.4[7.3 - 15.0]%,P < 0.01)。奎尼丁的总清除率更高(7.7[3.9 - 11.4]对3.4[1.8 - 4.6]毫升/分钟/千克,P < 0.01),但游离药物的清除率无差异(分别为32.2[14.6 - 50.4]对29.9[20.2 - 50.9]毫升/分钟/千克,P > 0.2)。3. 副作用较轻,包括两例服用奎尼丁后出现短暂性低血压。4. 两种药物均使校正心率后的QT间期(QTc)延长,从心脏传导“效应”室的消除速率相似(keo;奎宁为4.14[0.03 - 15.33]小时-1,奎尼丁为3.74[1.63 - 13.14]小时-1,P > 0.19)。使用线性浓度 - 反应模型,奎尼丁效应的截距(“阈值”)低于奎宁(P = 0.004),但斜率(游离药物浓度给定变化时QTc的变化)相似(P = 0.56)。(摘要截断于250字)

相似文献

引用本文的文献

4
Stereoselective Inhibition of the hERG1 Potassium Channel.立体选择性抑制 hERG1 钾通道。
Front Pharmacol. 2010 Nov 22;1:137. doi: 10.3389/fphar.2010.00137. eCollection 2010.
8
Quinine distribution in mice with Plasmodium berghei malaria.伯氏疟原虫感染小鼠体内奎宁的分布情况。
Eur J Drug Metab Pharmacokinet. 2003 Jan-Mar;28(1):11-20. doi: 10.1007/BF03190862.
10
Pharmacokinetic interactions of antimalarial agents.抗疟药的药代动力学相互作用。
Clin Pharmacokinet. 2001;40(5):343-73. doi: 10.2165/00003088-200140050-00003.

本文引用的文献

2
QUANTITATIVE DETERMINATION OF QUINIDINE IN PLASMA.血浆中奎尼丁的定量测定
Scand J Clin Lab Invest. 1963;15:553-6. doi: 10.1080/00365516309079786.
4
Clinical pharmacokinetics of quinidine.奎尼丁的临床药代动力学。
Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003.
5
Safety and efficacy of intravenous quinidine.
Am J Med. 1983 Jul;75(1):36-42. doi: 10.1016/0002-9343(83)91165-8.
7
Quinine disposition kinetics.奎宁处置动力学。
Br J Clin Pharmacol. 1983 Oct;16(4):399-403. doi: 10.1111/j.1365-2125.1983.tb02184.x.
8
Quinidine in falciparum malaria.奎宁在恶性疟中的应用。
Lancet. 1981 Nov 14;2(8255):1069-71. doi: 10.1016/s0140-6736(81)91275-7.
10
Binding of quinine to plasma proteins in falciparum malaria.
Am J Trop Med Hyg. 1985 Jul;34(4):681-6. doi: 10.4269/ajtmh.1985.34.681.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验